Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda, Wave Ink Antisense Pact for Neurological Diseases
February 22, 2018
- Novartis Japan Chief on Rare Paternity Leave, Looks to Lead by Example
February 22, 2018
- Bristol-Myers Japan Taps Ex-AZ Exec Hashigami as Development Chief
February 21, 2018
- Taniuchi Appointed as Santen President and COO
February 21, 2018
- Aducanumab Trial Tweak “Common Decision” to Boost Statistical Confidence: Biogen CEO
February 21, 2018
- Seikagaku to Run Add’l PIII for Lumbar Disc Herniation Drug in US
February 20, 2018
- Fujifilm Starts Japan PII for Radiopharmaceutical in Pheochromocytoma
February 20, 2018
- Dovobet Gel Wins Japan Approval: LEO/Kyowa Kirin
February 20, 2018
- Medical System Network Taps into Generic Business via Its Dispensing Pharmacy Chains, Aiming at Future Expansion
February 20, 2018
- Takeda’s Specialty Biz Unit Most Likely to Handle GI Meds, Entyvio Launch Apparently Eyed
February 20, 2018
- Takeda to Revamp Sales Offices as Japan Shifts to Community-Based Care System
February 20, 2018
- Lenvima OK’ed for UK Health Coverage in Thyroid Cancer
February 19, 2018
- Oncolys Invests in US Immuno-Oncology Startup
February 19, 2018
- Sumitomo Dainippon Halts Development of FXR Agonist in Japan, South Korea
February 16, 2018
- Daiichi Sankyo Files Mirogabalin in Japan for PNP
February 16, 2018
- Global Brands Drive Otsuka’s Pharma Sales in 2017
February 15, 2018
- Astellas Picks Up US Upstart, Grabs Full Access to Universal Donor Cell Technology
February 15, 2018
- Sumitomo Dainippon Sues 2 Gx Makers over Latuda, Delays New 5-Year-Plan Announcement
February 15, 2018
- Teijin, SanBio Terminate License Agreement for Stroke Treatment; Development and Marketing Rights to Revert to SanBio
February 15, 2018
- Lonasen Patch Hits PIII Primary Target in Japan, Filing Planned in 1st Half of FY2018: Sumitomo Dainippon, Nitto Denko
February 15, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…